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Abstract 
The global hepatitis strategy calls for increased effort to diagnose those infected, with a target 
of 90% diagnosed by 2030. Scotland’s Action Plan on Hepatitis C included awareness-raising 
campaigns, undertaken during 2008-2011, to promote testing by General Practitioners.  We 
examined HCV testing practice among general practitioners before and following these 
campaigns. Scottish general practitioners  were surveyed, using Dillman’s method, in 2007 
and 2013; response rates were 69% and 60%, respectively.  Most respondents offer testing 
when presented with a risk history (86% in 2007, 88% in 2013) but only one fifth actively 
sought out risk factors (19 in 2007, 21% in 2013).  Testing was reportedly always/almost 
always/usually offered to people who inject drugs (84% in 2007, 87% in 2013). Significant 
improvements in the offer of testing were reported in patients with abnormal LFTs (41% in 
2007, 65% in 2013, p<0.001) and who had received medical/dental treatment in high 
prevalence countries (14% in 2007, 24% in 2013, p=0.001).   In 2013, 25% of respondents 
had undertaken HCV-related Continued Professional Development.  This group were 
significantly more likely to actively seek out risk factors (p=0.009) but only significantly 
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more likely to offer a test to patients who had received medical/dental treatment in high 
prevalence countries (p=0.001).  Our findings suggest that government-led awareness-raising 
campaigns have limited impact on general practitioners’ testing practices.  If the majority of 
the HCV infected population are to be diagnosed, practitioner-based or physician-centred 
interventions should be considered alongside educational initiatives targeted at professional.  
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Introduction  
With the development of highly effective Direct Acting Antiviral (DAA) treatment for 
Hepatitis C virus (HCV) infection, control of the disease is now possible [1].  However, to 
achieve this goal it will be necessary to find those individuals who are infected but remain 
undiagnosed.  Across European countries, there is wide variation in the proportion of infected 
persons who have been diagnosed, from France where the majority (56% in 2005) have been 
diagnosed to Poland and other Central European countries where more than 80% are believed 
to remain undiagnosed [2,3].  
When the Hepatitis C Action Plan for Scotland was launched in 2006, almost two-thirds of 
the estimated 38,000 chronic HCV infections in Scotland remained undiagnosed [4].  A key 
aim of the Action Plan was to identify these undiagnosed individuals.  Primary care was 
considered an appropriate setting to focus awareness raising activities as previous studies 
have demonstrated increases in both testing and diagnoses as a result of targeted screening in 
the general practice setting [5-8]. 
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On a national level, a number of awareness-raising activities undertaken during Phase II of 
the Action Plan (2008-2011) were aimed specifically at GPs [9].  These included a Chief 
Medical Officer’s letter, an information website for professionals 
(www.hepatitisscotland.org.uk), adverts in the medical press and an information pack 
(including a leaflet, mouse mat and other items that prompted them to think of HCV and 
directing them to the website).  The Royal College of General Practitioners introduced a 
“Certificate in the Detection, Diagnosis and Management of Hepatitis B and C in Primary 
Care” delivered through online and face-to-face Continued Professional Development (CPD) 
training in 2011[10].  
Here we present results of two surveys of GPs in 2007 and 2013 to i) describe GPs’ testing 
practices, ii) examine changes in practice following the Action Plan, and iii) determine 
physician-perceived barriers to HCV testing in primary care. 
 
Materials and Methods 
GP survey population 
GP training practices, where newly qualified doctors and medical students gain experience of 
general practice, were identified as an appropriate sample to survey in 2007 as contact details 
were readily available and in the public domain [11]. The training lead for each practice was 
asked to complete the survey.  The training lead for all but two of the GP training practices 
throughout Scotland (n=235) were included in the survey; this represented 23% of all general 
practices in Scotland at that time (233/1030).  Of the two excluded from the survey, one GP 
was on long-term sick leave and one addressee was unknown. To ascertain the urban/rural 
distribution of each practice, the Scottish Government classification scheme (2005-2006) was 
employed [12].  The same GPs, regardless of whether they retained their training lead status, 
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were surveyed in 2013. Seventeen GPs were not surveyed in 2013 as they had since moved 
practice (13), retired (3), or were on maternity leave (1).  
Questionnaire  
A questionnaire was designed to determine GPs’ HCV testing practices using a combination 
of open and closed questions. This included questions on the characteristics of the GP’s 
practice (NHS board and urban/rural category), whether the GP tests for HCV, how many 
HCV tests are undertaken per month, how many HCV patients diagnosed in the last year and 
the number of HCV patients currently under the GP’s care.    How frequently the offer on an 
HCV test would be made to key risk groups (as specified in the Scottish Intercollegiate 
Guidelines Network (SIGN) guidance) [13] was asked.  Responses for this question used the 
scale “Always/almost always”, “Usually”, “About half the time”, “Sometimes”, or 
“Never/rarely”.  GP perceived barriers (i) associated with the client and (ii) associated with 
the practice were also asked and responses for this question used the scale “Strongly agree”, 
“Agree”, “Disagree”, “Strongly disagree”. 
Piloting of this questionnaire was undertaken with GPs associated with i) the Greater 
Glasgow and Clyde NHS Board Managed Care Network, and ii) the evaluation of a GP-based 
HCV screening interventions in Glasgow [7,8].  The 2013 questionnaire included all of the 
questions from the 2007 questionnaire with the addition of questions to i) explore access to 
the Action Plan awareness-raising initiatives implemented following the initial survey, and ii) 
whether the respondents considered future delivery of treatment through Primary Care may 
improve treatment uptake. 
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Implementation of survey 
The survey was implemented, during April/May 2007 and October/November 2013, using 
Dillman’s Tailored Design Method [14].  This consisted of five key elements which have 
been shown to improve the response to postal surveys: i) a respondent-friendly questionnaire, 
ii) five contacts with the questionnaire recipient during the survey period, iii) inclusion of a 
stamped addressed envelope, iv) personalised correspondence, and v) a £15 book token as an 
incentive for completion of the questionnaire. The voluntary and confidential nature of the 
survey was emphasised. A copy of the survey was mailed to the GP(s) responsible for 
training in every practice.  
Data analysis 
Data were managed and analysed using the Statistical Package for Social Sciences (SPSS) 
Version 21.0 [15].   
Frequencies for each survey question were analysed.  For analysis of frequency key 
population groups are offered an HCV test answers were combined from five categories to 
three: “Always/Almost always/Usually”, “About half the time/Sometimes”, and 
“Never/Rarely”.  For analysis of barriers to HCV testing, answers were combined from four 
categories to two: “Strongly agree/Agree” and “Disagree/Strongly disagree”. Where 
appropriate, the significance of any differences between the 2007 and 2013 were analysed 
using Kruskal Wallis test or Fishers Exact test.   
For 2013 responses, HCV training level was stratified into three categories: “CPD” (those 
who have undertaken a formal CPD course, for example courses provided by NHS Education 
Scotland or the Royal College of General Practitioners), “Awareness raising” (those who 
reported receiving at least one of Chief Medical Officer's letter, Hepatitis C GP information 
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pack, or online training resources and did not report CPD), and “None”.   Comparisons of 
training level by likelihood of offering an HCV test to key population groups and 
circumstances under which an HCV test were undertaken using Kruskal Wallis.  Where the 
significance of this was less than p=0.05, a post hoc pairwise analysis was used to compare 
the significance among the training levels.   A large proportion of the “None” group reported 
self-directed reading  to ensure their HCV knowledge is current and so a sensitivity analysis 
comparing this group with the CPD group was undertaken.  
 
Results 
Characteristics of surveyed GP training practices (Appendix) 
The practices of surveyed GPs accounted for 23% (233/1030) of all practices in Scotland in 
2007 and 22% (217/991) of all practices in Scotland in 2013. Surveyed practices were more 
concentrated in urban areas (65% of all practices in urban areas in 2007 and 2013 versus 67% 
of surveyed practices in 2007 and 71% in 2013).  Respondents were less concentrated in 
urban areas 59% in 2007 and 51% in 2013.  At least 60% of the 233 surveyed GPs responded 
to each survey (69% in 2007 and 60% in 2013).    
HCV Testing and Diagnosis (Tables 1 and 2) 
Most respondents reported testing for HCV (91% in 2007 and 90% in 2013), almost all of 
whom reported testing fewer than 10 patients in an average month (98% in both surveys). 
HCV caseload had increased over time with 30% of respondents in 2007 reporting having 
more than five HCV patients, compared with 45% of respondents in 2013 (p=0.024).   
Among those testing for HCV, more than 85% reported they would “opportunistically offer a 
test when the client presents with a risk history” (86% in 2007, 88% in 2013); almost three 
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quarters reported they would “opportunistically offering a test when the client presents with a 
medical indication of liver disease” (74% in 2007, 72% in 2013), around half reported testing 
“when requested” (52% in 2007, 48% in 2013), less than a quarter “actively seek out risk 
factors” (19% in 2007, 21% in 2013), and the lowest proportion reported testing “as part of a 
routine screen” (15% in both surveys).  There were no statistically significant differences 
across the surveys.   
Key populations to test for HCV (Table 3) 
Variation of approach among GPs regarding the key populations to test for HCV was 
apparent.  Respondents reported that they would “Always”/ “Almost always”/ “Usually” 
offer an HCV test to patients with abnormal Liver Function Tests (LFTs) (41% in 2007, 65% 
in 2013, p<0.001), current People Who Inject Drugs (PWID) (84% in 2007, 87% in 2013, 
p0.383), Previous PWID (82% in 2007, 81% in 2013, p=0.754), HIV positive patients (84% 
in 2007, 88% in 2013, p=0.378), blood product recipients (22% in 2007, 26% in 2013, 
p=0.154), blood transfusion recipients (14% in 2007, 24% in 2013, p=0.135), individuals 
who received medical/dental treatment in high HCV prevalence countries (14% in 2017, 26% 
in 2013, p=0.001), and those with sexual or household contact with an HCV infected person 
(71% in 2007, 80% in 2013, p=0.157) 
Barriers to testing (Table 4) 
The surveys explored barriers to testing associated with the client as well as those associated 
with the practice as perceived by the responding GPs. Among’ barriers to testing related to 
the client, GPs most frequently “strongly agree/agreed” the client not identifying him/herself 
as being at risk (87% in 2007, 80% in 2013),   poor awareness of HCV among clients (83% in 
2007, 80% in 2013) and HCV not being a priority for the client (68% in 2007,64% of GPs in 
2013).  Across both surveys, the majority of respondents “disagreed” or “strongly disagreed” 
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(85% in 2007, 91% in 2013) that poor acceptability of testing services was a barrier to testing 
associated with clients.  There were no significant changes across the surveys for barriers 
associated with the client. 
 
GPs’ perceptions of barriers to testing associated with the practice were more variable across 
the surveys. Respondents “strongly agreed/agreed” that the following were barriers 
associated with the practice but the proportion decreased across the surveys: limited 
knowledge of testing protocols and who to test (73% in 2007, 50% in 2013, p<0.001), poor 
awareness among staff (66% in 2017, 51% in 2013, p=0.011), lack of time for pre and post 
test counselling (61% in 2007, 47% in 2013, p=0.019), insufficient staff with appropriate skill 
for counselling (56% in 2017, 31% in 2013, p<0.001), limited knowledge of who, and where 
to refer diagnosed patients (32% in 2007, 15% in 2013, p=0.001), waiting time for clinical 
appointment following initial specialist referral (24% in 2007, 10% in 2013, p=0.003). The 
majority of respondents strongly agree/agree that inappropriate environment for testing was a 
barriers to testing and there was no significant difference across surveys (89% in 2007, 92% 
in 2013, p=0.384).  Conversely, a minority strongly agree/agree that “HCV is not an item of 
payment” was a barrier to testing and there was no difference across surveys (25% in 2007, 
21% in 2013, p=0.402).   
Contact with Hepatitis C awareness-raising and training initiatives  
In 2013, more than half of respondents (57%) had heard of the Scottish Hepatitis C Action 
Plan. Of 2013 respondents 25% reported having undertaken a formal CPD course, 59% 
reported being exposed to “Awareness raising” (having receiving at least one of Chief 
Medical Officer's letter, Hepatitis C GP information pack, or online training resources and 
did not report CPD), and 16% had received no HCV training or awareness-raising.    
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Differences in testing practice by contact with awareness-raising initiatives (Tables 5 and 
6) 
Training level was found to be significantly associated with the proportion of respondents 
who reported “Always”/“Almost always”/“Usually” only for individuals who received 
medical/dental treatment in high HCV prevalence countries (39% for CPD, 15% for 
Awareness raising, 10% for none, p=0.002). In the pairwise analysis, the CPD group 
compared with the None group (p=0.001) and the Awareness raising group compared with 
the None group (p=0.024) were significantly different. CPD compared with Awareness 
raising was not significantly different (p=0.265). 
With regard to circumstances where an HCV test would be offered, the only significant 
difference by training group for actively seeking out risk factors.  Among those reporting 
CPD, 31% actively sought risk factors for testing, 18% for the Awareness raising group, and 
none of the group who had received no CPD or awareness raising (p=0.012).  In the pairwise 
analysis, only CPD compared with the None group was significant (p=0.009). 
For those who reported not attending or undertaking training/CPD events for Hepatitis C, 
almost three quarters (73%) ensured their knowledge of hepatitis C was current through self-
directed reading.  A sensitivity analysis comparing this group with the CPD group found that 
the CPD group  were significantly more likely to “Always”/“Almost always”/“Usually” offer 
at test to Current PWID (97% CPD, 75% self-directed reading, p=0.023) and those receiving 
medical/dental treatment in high prevalence countries (40% CPD, 13% self-directed reading, 
p=0.003).  Similarly, the CPD group was more likely to actively seek out risk factors (32% 
CPD, 0% self-directed reading, p=0.005).  
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Delivery of Hepatitis C treatment in Primary Care 
Eighty-one percent (109/135) of respondents in 2013 agreed that delivery of new oral 
treatments for hepatitis C, which are more effective, shorter in duration and much better 
tolerated, in primary care could improve treatment uptake.  Of the 19% who did not agree, 
concerns about resources, requirement of specialist support and the importance of training 
were indicated.  
 
Discussion 
Summary of findings 
Despite the first publication of the Scottish Intercollegiate Guidelines Network (SIGN) 
guidelines [14] on HCV in 2006, we found variation in GPs’ testing practice across the key 
populations when surveyed the following year. While the proportion of respondents reporting 
that they would offer a test to current/former PWID and HIV positive patients was high, the 
less common risk groups such as historical blood and blood products recipients or those who 
had received medical or dental treatment in high prevalence countries was considerably 
lower. Most respondents reported offering a test when presented with a risk or medical 
prompt but less than a quarter actively seek out risk factors for HCV.   
 
Across the two surveys, despite numerous awareness-raising activities at both a national and 
local level during Phase II of the Hepatitis C Action Plan (2008-2011) [9], improvements in 
testing practice were limited.  The only significant increases in HCV testing awareness were 
for patients with abnormal liver function tests (LFTs) and for patients who had received 
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medical or dental treatment in high HCV prevalence countries.  While physician-perceived 
barriers to testing related to the client remained largely the same across both surveys, 
respondents consistently reported fewer perceived barriers related to the practice in 2013 than 
in 2007.   
The majority of respondents recalled being exposed to some form of HCV awareness-raising, 
but only a minority had undertaken formal, HCV-related CPD. Among those who had 
undertaken CPD, actively seeking out risk factors and offering an HCV test to patients who 
had received medical/dental treatment in high prevalence countries were the only significant 
differences in practice than those who had not.   
While this demonstrates some effectiveness of CPD, these improvements were modest and 
less than a third of the CPD group reported actively seeking risk factors.  This is the optimal 
approach to case-finding, particularly among those whose risk may not be immediately 
apparent, such as former PWID, or those who remain asymptomatic. None of the respondents 
who had received neither CPD nor awareness-raising reported actively seeking out risk 
factors and only 75% of this group would offer an HCV test to a current PWID.  
Validity of Observations 
This is the first study to examine GPs’ practices related to HCV in the context of a major 
government policy and investment.  This paper presents the views and practice prior to, and 
following, the Action Plan awareness-raising initiatives.  A key limitation of this study is the 
inability to undertake a paired analysis across GPs responding twice.  As the 2007 survey was 
undertaken as part of a needs assessment project, it was not envisioned at that time that the 
survey would later be repeated.  However, the 2007 survey provided the best available 
baseline data for knowledge and practice prior to the implementation of the awareness-raising 
campaigns.   
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The use of GP training leads may not be representative of the GP population in Scotland.  
The practices of the surveyed GPs were representative of all Scottish practices in terms of 
their NHS board affiliation and urban/rural distribution. However, given the likelihood that 
GP training practice staff will be kept informed of current guidelines for teaching purposes, 
although this will be the case for a wide variety of conditions rather than specialising in 
HCV, these results may indicate a high water mark of knowledge. A 2011 UK-wide survey of 
medical trainers (including GPs) found that GPs were responsible for a median of two 
trainees.  Half reported having no additional contracted hours for such supervision but 
typically spend three hours a week on training [16].  This may limit the additional effort 
made on maintaining specific HCV skills.  There will also be GPs with high HCV caseload, 
working in a high prevalence area, or with a particular interest in HCV who may not have 
been surveyed but who have better HCV testing practice.   
Comparison with Existing Literature 
Some previous studies reported poor knowledge of HCV among GPs, such as not incorrect 
interpretation of test results or the belief that blood transfusion continued to be a risk even 
after the introduction of screening.  Generally, the proportion of GPs reporting that PWID 
should be offered an HCV test is in excess of 80% but this is reduced for the less common 
risk groups such as blood product recipients or sexual contacts, as is consistent with our 
results.  Several of these studies also indicate that the offer of a test is sub-optimally made as 
the GPs rarely actively seek risk factors [17-21].  None of these studies were in the context of 
a major policy such as the Scottish Hepatitis C Action Plan.   
Our findings, particularly the high proportion of respondent agreeing that lack of time for pre 
and post test counselling is a barrier to testing and the low proportion of respondents actively 
seeking out risk factors, are consistent with a case-finding study in England, in which GPs 
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reported confidence in their knowledge of HCV but cited short consultation times and 
remembering to offer a test as the main barriers to testing [22].  That study suggested 
electronic reminders within the patient management system may increase the offer of an 
HCV test.  A 2015 meta-analysis found that practitioner-based interventions that included in-
practice support had the most impact on increasing test uptake (increasing by 3.5times 
compared with no intervention) while media or information based campaigns had less impact 
(increase test uptake by 1.5 times compared with no intervention) [23].  This is consistent 
with our findings that GPs who had undertaken CPD were more likely to actively seek out 
risk factors than those who had received no CPD or awareness-raising.   
Significance of research 
During the interval between the two surveys, the proportion of Scotland’s HCV infected 
population who were diagnosed was estimated to have increased from 38% to 55% [24, 25]; 
one of the key drivers of the increase was the introduction of Dried Blood Spot testing in 
community drug services for people who, generally, are still injecting drugs [26,27]. It is 
estimated, however, that the majority of the 45% of HCV infected people who remained 
undiagnosed as at 2013, were people who were no longer injecting. Thus, despite over 88% 
of GP’s stating that they always offer an HCV test to someone they knew to have injected 
drugs in the past, thousands of former PWID in Scotland remain undiagnosed. 
It is likely that many of these  will have been to their GP at least once during the six year 
interval between surveys but identification would require actively seeking out their past 
injecting risk. Where the patient’s injecting history was short or further in the past, it will be 
less likely that the risk is presented in an opportunistic manner. 
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Improved case-finding among non-PWID groups is of particular importance in Scotland 
following the publication of the Penrose Inquiry Final Report, which recommended that “the 
Scottish Government takes all reasonable steps to offer an HCV test to everyone in Scotland 
who had a blood transfusion before September 1991 and who has not been tested for HCV” 
[28].  Our findings suggest the status quo would be insufficient to attain this goal and further 
targeted awareness-raising among the patient group may also be required. 
A growing body of evidence has demonstrated that significant increases in HCV screening 
can be achieved through electronic clinical reminders in patient management systems [22, 
29,30].  Such interventions are relatively easy to implement as they require one-off changes 
to the patient management system and can be rolled out across multiple users and practices.  
Similar increases in HCV testing have been observed following the introduction of a physical 
reminder attached to patient notes [31].    A qualitative analysis of HCV testing and 
diagnoses delay (where a diagnoses was more than 15 years after suspected transmission) 
found that, patients may not believe themselves to be at risk and are less likely to volunteer 
risk information but prompts to discuss risks may increase testing [32].  
Based on results from our study, an electronic reminder that encouraged a GP to ask about 
the patient’s risk factors for HCV would remove the need for the GP to actively seek these 
out.  Such an approach could be used to overcome the reported physician-perceived barriers 
of “poor awareness among staff” and “limited knowledge of testing protocols and who to be 
tested”. This approach would have an impact on consultation times  but for those individuals 
with a past risk, for example former PWID or historic blood transfusion recipients, it is likely 
that a one-off screening would be required.  The SIGN guidelines for HCV recommend 
annual testing only for those who remain at risk of infection [13].  
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Half of survey respondents agreed that lack of time for pre and post test counselling is a 
barrier to HCV testing.  A 2001 WHO consultation on increasing HIV testing noted that in 
some settings informed consent was an acceptable replacement for pre-test counselling while 
post-test counselling remained essential following a positive results [33,34].  An extension of 
this would be to adopt an opt-out model, where patients receiving any routine blood test 
would also be tested for a blood-borne virus, which removes the requirement for a discussion 
on risk factors.  This has been demonstrated to have a positive impact on HCV testing in 
hospital settings [35, 36].  A recent study in Ireland on opt-out testing for all patients having 
routine blood tests in general practice described low levels of opt-out (10.5%) but the yield 
for case-finding was low with only 2 new HCV and hepatitis B diagnoses made among more 
than 1000 patients over a 6 month period [37].  
Improvements in primary care screening have been observed through the use of financial 
incentives such as Quality and Outcomes Framework (QOF) payments, where GPs in 
Scotland received additional payments for undertaking clinical and public health activities 
such as ensuring patients aged over 45 or over had a record of blood pressure or the 
proportion of women aged between 20 and 60 who have a record of a cervical screen in the 
preceding 5 years.  These improvements may continue after incentives are withdrawn [38, 
39].  While a minority of respondents (25% in 2007 and 21% in 2013) agreed that HCV not 
being an item of payment was a barrier to testing, such incentives may promote increases in 
testing nonetheless.  Further study into the feasibility of these models in Scotland is 
recommended.  The majority of respondents agreed that, if properly resourced, a move to the 
delivery of new HCV treatments to primary care may improve uptake of treatment.  A 
clinical trial in the UK found that integrating HCV treatment in primary care with other 
services for the PWID population also resulted in increases of HCV testing and diagnoses 
[40].  This study included a clinical nurse specialist and consistent with previously discussed 
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findings that practice-based support interventions result in the largest increases in HCV 
testing and diagnoses [7, 8, 23].   
The World Health Organisation (WHO) has set a target for diagnosing 30% of HCV 
infections by 2020 and 90% by 2030 [41].  The proportion of diagnosed infections varies by 
country, with some countries, such as Australia, in excess of 80% and others, such as India, 
where it may be as low as 5% [42, 43].  Our results, based on the experience of the Scottish 
Action Plan, may be used to inform other countries seeking to meet the WHO targets.  While 
directing funding to awareness-raising activities for GPs may result in some modest increases 
in testing and diagnoses in other countries, other more physician-centred measures should 
also be considered.   
As we enter the era of Direct Acting Antiviral therapy, which offers both the possibility of 
control of Hepatitis C and a move of treatment from secondary to primary care, the 
importance of general practitioners’ HCV testing practice has never been more critical.  The 
impact of government-led awareness-raising campaigns was limited and it is clear that to 
identify the undiagnosed population, particularly those with a distant history o injecting drugs 
that is less likely to be apparent or the less common risk groups such as historic blood 
transfusion recipients, GPs require additional support and direction to expand HCV testing. 
Further measures, such as additional payments to GPs, electronic reminders or adoption of 
opt-out testing, should be considered alongside educational initiatives targeted at 
professionals and operate in tandem with awareness-raising among at risk, or formerly at risk, 
groups.  
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Appendix: Characteristics of all GP practices in Scotland, surveyed practices, and responding practices by year 
 
        
Characteristics   General practices Practices surveyed  Practices responding to survey 
   2007 2013 2007 2013 2007 2013 
    
N (% of Total) N (% of Total) 
N (% of All 
Practices) 
N (% of All 
Practices) 
N (% of 
Surveyed) N (% of Surveyed) 
NHS Board Greater Glasgow & 
Clyde 274 (27%) 263 (27%) 53 (19%) 49 (19%) 37 (70%) 27 (51%) 
  Lothian 127 (12%) 125 (13%) 29 (23%) 28 (22%) 22 (76%) 27 (93%) 
  Tayside 71 (7%) 68 (7%) 26 (37%) 22 (32%) 17 (65%) 12 (46%) 
  Grampian 84 (8%) 80 (8%) 25 (30%) 24 (30%) 15 (60%) 12 (48%) 
  Other 474 (46%) 455 (46%) 100 (21%) 94 (21%) 69 (69%) 62 (62%) 
  Total 1030 991 233 (23%) 217 (22%) 160 (69%) 140 (60%) 
             
Urban/rural 
classification 
Urban 667 (65%) 648 (65%) 157 (24%) 154 (24%) 93 (59%) 81 (51%) 
Rural 362 (35%) 343 (35%) 75 (21%) 63 (18%) 66 (88%) 59 (79%) 
  Unknown 1 (0%) 0 (0%) 1 (100%) 0 (0%) 1 (100%) 0 (0%) 
  Total 1030 991 233 (23%)  217 (22%) 160 (69%) 140 (60%) 
*Other refers to NHS Ayrshire & Arran, Borders, Dumfries & Galloway, Forth Valley, Fife, Highland, Lanarkshire, Orkney, Shetland and Western 
Isles   
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Table 1: HCV related activities of GP respondents by survey 
 
    2007 2013 
Kruskal Wallis 
test 
Characteristic   N (%) N (%) P-value 
No of patients with HCV under care None 13 (8%) 9 (6%) 0.024 
 1-5 94 (59%) 64 (46%)  
 6-10 18 (11%) 29 (21%)  
 11-20 21 (13%) 19 (14%)  
 >20 10 (6%) 14 (10%)  
 
Not 
Known 4 (3%) 5 (4%)  
     
Test for HCV Yes 145 (91%) 125 (90%) 0.7 
 No 15 (9%) 15 (10%)  
     
Number tested in an average month <10 142 (98%) 125 (98%) 0.757 
 11+ 2 (1%) 2 (2%)  
 
Not 
Known 1 (1%) 0 (0%)  
     
Number diagnosed in last 12 months 0-5 139 (97%) 125 (98%) 0.005 
  6+ 5 (3%) 2 (2%)    
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Table 2: Circumstance under which respondents would offer an HCV test, by survey 
 
   Yes No  
Response*  N (%) N (%) Fisher Exact test 
Actively seek out risk factors 2007 28 (19%) 117 (81%) 0.762 
  2013 26 (21%) 98 (79%)   
          
Opportunistically offer test when client presents history 2007 125 (86%) 20 (14%) 0.719 
  2013 109 (88%) 15 (12%)   
          
Opportunistically offer when client presents medical indication of 
liver disease 
2007 108 (74%) 37 (26%) 0.679 
2013 89 (72%) 35 (28%)   
          
Test when requested 2007 76 (52%) 69 (48%) 0.464 
  2013 59 (48%) 65 (52%)   
          
Test as part of routine screen 2007 22 (15%) 123 (85%) 1 
  2013 18 (15%) 106 (85%)   
*Multiple responses were acceptable         
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Table 3: Likelihood of respondents offering an HCV test to different patient populations on becoming aware of risk information 
Population  Survey Response 
Kruskal Wallis 
test 
    
Always/ almost 
always/Usually 
About half the 
time/Sometimes Never/ rarely   
Patients with abnormal LFTs 2007 58 (41%) 63 (45%) 20 (14%) 
<0.001 
  2013 84 (65%) 43 (33%) 3 (2%) 
            
Current IDU 2007 117 (84%) 20 (14%) 3 (2%) 
0.393 
  2013 111 (87%) 13 (10%) 3 (2%) 
            
Previous IDU 2007 117 (82%) 24 (17%) 2 (1%) 
0.754 
  2013 104 (81%) 21 (16%) 4 (3%) 
            
HIV positive 2007 108 (84%) 12 (9%) 8 (6%) 
0.378 
  2013 112 (88%) 9 (7%) 6 (5%) 
            
Blood products (before 1987) 2007 31 (22%) 37 (27%) 71 (51%) 
0.154 
  2013 32 (26%) 41 (33%) 51 (41%) 
            
Blood Transfusion (before 1992) 2007 27 (19%) 35 (25%) 77 (55%) 
0.135 
  2013 29 (24%) 38 (31%) 56 (46%) 
            
Medical/Dental in high prevalance countries 2007 19 (14%) 38 (27%) 83 (59%) 
0.001 
  2013 33 (26%) 43 (34%) 51 (40%) 
            
Sexual/Household Contact with HCV infected 2007 100 (71%) 33 (24%) 7 (5%) 
0.157 
  2013 101 (80%) 19 (15%) 7 (6%) 
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Table 4: Barriers to Hepatitis C testing Associated with (A) the Client and (B) the Practice 
 
Barriers to Hepatitis C Testing 
Survey 
Response 
Total 
Kruskal 
Wallis   
Strongly 
Agree / Agree 
Disagree / 
Strongly Disagree 
  N (%) N (%) P value 
(A) Associated with the client:           
HCV is not a priority or relevant to the 
client at the time 
2007 106 (68%) 50 (32%) 156 0.532 
2013 89 (64%) 49 (36%) 138   
Clients do not identify as being, or at 
some point being, at risk for HCV 
2007 135 (87%) 20 (13%) 155 0.109 
2013 109 (80% 27 (20%) 136   
Stigma 2007 76 (49%) 79 (51%) 155 0.283 
  2013 59 (43%) 79 (57%)  138   
Poor acceptability of testing services 2007 23 (15%) 133 (85%) 156 0.165 
  2013 13 (9%) 125 (91%) 138   
Poor awareness of HCV among clients 2007 131 (83%) 27 (17%) 158 0.583 
  2013 111 (80%) 27 (20%) 138   
Poor venous access 2007 32 (21%) 123 (79%) 155 0.502 
  2013 33 (24%) 105 (76%) 138   
Perceived problems of confidentiality 2007 24 (15%) 131 (85%) 155 0.661 
  2013 19 (14%) 120 (86%) 139   
Fear of services 2007 38 (25%) 117 (75%) 155 0.257 
  2013 42 (30%) 96 (70%) 138   
Fear of diagnosis 2007 103 (66%) 52 (34%) 155 0.414 
  2013 86 (62%) 53 (38%) 139   
(B) Associated with the practice:           
Poor awareness among staff 2007 103 (66%) 54 (34%) 157 0.011 
  2013 71 (51%) 68 (49%) 139   
Inappropriate environment for testing 2007 139 (89%) 17 (11%) 156 0.384 
  2013 128 (92%) 11 (8%) 139   
Insufficient staff with appropriate skill 
for counselling 
2007 88 (56%) 69 (44%) 157 <0.001 
2013 44 (31%) 96 (69%) 140   
Limited knowledge of testing protocols 
and who to be tested 
2007 115 (73%) 43 (27%) 158 <0.001 
2013 70 (50%) 69 (50%) 139   
Limited knowledge of who, and where, 
to refer diagnosed patients 
2007 50 (32%) 107 (68%) 157 0.001 
2013 21 (15%) 118 (85%) 139   
Lack of time for pre and post test 
counselling 
2007 96 (61%) 61 (39%) 157 0.019 
2013 66 (47%) 73 (53%) 139   
HCV is not an item of payment 2007 39 (25%) 116 (75%) 155 0.402 
  2013 29 (21%) 109 (79%) 138   
Waiting time for clinical appointment 
following initial specialist referral 
2007 35 (24%) 113 (76%) 148 0.003 
2013 14 (10%) 124 (90%) 138   
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Table 5: Likelihood of GPs offering an HCV test to different patient populations by access to training/awareness raising activities, responses to 2013 
survey 
 
    
Always/ almost 
always/Usually 
About half the 
time/Sometimes Never/ rarely 
Kruskal 
Wallis Pairwise 
Factor Training Level N (%) N (%) N (%) P Value Comparison P Value 
Patients with abnormal LFTs CPD
1
 22 (67%) 11 (33%) 0 (0%) 0.678     
  Awareness raising
2
 51 (66%) 23 (30%) 3 (4%)       
  None 11 (55%) 9 (45%) 0 (0%)       
Current IDU CPD 30 (94%) 2 (6%) 0 (0%) 0.134     
  Awareness raising 66 (88%) 7 (9%) 2 (3%)       
  None 15 (75%) 4 (20%) 1 (5%)       
Previous IDU CPD 28 (85%) 5 (15%) 0 (0%) 0.437     
  Awareness raising 62 (82%) 10 (13%) 4 (5%)       
  None 14 (70%) 6 (30%) 0 (0%)       
HIV positive CPD 30 (91%) 3 (9%) 0 (0%) 0.47     
  Awareness raising 66 (89%) 3 (4%) 5 (7%)       
  None 16 (80%) 3 (15%) 1 (5%)       
Blood products (before 1987) CPD 10 (32%) 11 (35%) 10 (32%) 0.221     
  Awareness raising 19 (26%) 24 (33%) 30 (41%)       
  None 3 (15%) 6 (30%) 11 (55%)       
Blood Transfusion (before 1992) CPD 10 (32%) 11 (35%) 10 (32%) 0.124     
  Awareness raising 16 (22%) 22 (31%) 34 (47%)       
  None 3 (15%) 5 (25%) 12 (60%)       
Medical/Dental in high 
prevalence countries 
CPD 12 (39%) 12 (39%) 7 (23%) 0.002     
Awareness raising 19 (25%) 28 (37%) 29 (38%)       
  None 2 (10%) 3 (15%) 15 (75%)       
            CPD vs Awareness raising 0.265 
            CPD Vs None 0.001 
            
Awareness raising vs 
None 0.024 
Sexual Contact CPD 28 (90%) 2 (6%) 1 (3%) 0.159     
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  Awareness raising 59 (78%) 14 (18%) 3 (4%)       
  None 14 (70%) 3 (15%) 3 (15%)       
1 Formal CPD for example courses provided by NHS Education for Scotland or the Royal College of General Practitioners        
2 Respondants reported receiving at least one of Chief Medical Officer's letter, Hepatitis C GP information pack, or online training resources and did not report CPD   
 
 
Table 6: Circumstances under which GPs would offer an HCV test by access to training/awareness raising activities, responses to 2013 survey 
 
    Yes No Krusak Wallis Pairwise 
Factor Training Level N (%) N (%) P Value Comparison P Value 
Actively seek out risk factors CPD
1
 11 (31%) 24 (69%) 0.012     
  Awareness raising
2
 15 (18%) 68 (82%)       
  None 0 (0%) 22 (100%)       
          CPD vs Awareness raising 0.268 
          CPD Vs None 0.009 
          
Awareness raising vs 
None 0.160 
Opportunistically offer test when client 
presents history 
CPD 31 (89%) 4 (11%) 0.397     
Awareness raising 65 (78%) 18 (22%)       
  None 17 (77%) 5 (23%)       
Opportunistically offer when client 
presents medical indication 
CPD 26 (74%) 9 (26%) 0.08     
Awareness raising 55 (66%) 28 (34%)       
  None 10 (45%) 12 (55%)       
Test when requested CPD 19 (54%) 16 (46%) 0.348     
  Awareness raising 35 (42%) 48 (58%)       
  None 8 (36%) 14 (64%)       
Test as part of routine screen CPD 4 (11%) 31 (89%) 0.665     
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  Awareness raising 13 (16% 70 (84%)       
  None 2 (9%) 20 (91%)       
1 Formal CPD for example courses provided by NHS Education for Scotland or the Royal College of General Practitioners      
2 Respondants reported receiving at least one of Chief Medical Officer's letter, Hepatitis C GP information pack, or online training resources and did not report 
CPD   
 
 
